SMG
SABS icon

Spectrum Management Group’s SAB Biotherapeutics SABS Stock Holding History

Spectrum Management Group’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$4K Hold
503
– – ﹤0.01% 220
2022
Q2 		$7K Hold
503
– – ﹤0.01% 202
2022
Q1 		$19K Hold
503
– – ﹤0.01% 192
2021
Q4 		$39K Buy
+503
New +$47.2K 0.01% 165

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Mariner
Mariner Overland Park, Kansas $85.7B AUM 24.21% 1-Year Est. Return

Spectrum Management Group's SABS Position: Q3 2022 in Review

Spectrum Management Group held its SAB Biotherapeutics (SABS) position steady in Q3 2022 at 503 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #220.

Spectrum Management Group first reported a position in SABS in Q4 2021 and has held it in 4 quarters since. The position peaked at $39K in Q4 2021. 40 funds tracked by Wall St. Rank hold SABS as of Q3 2022.

  • Spectrum Management Group held 503 shares of SAB Biotherapeutics worth $4K as of Q3 2022.
  • Spectrum Management Group left its SAB Biotherapeutics share count unchanged in Q3 2022.
  • SAB Biotherapeutics made up ﹤0.01% of Spectrum Management Group's portfolio in Q3 2022, its #220 holding.
  • Spectrum Management Group first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 4 quarters since.
  • Spectrum Management Group's SAB Biotherapeutics position peaked at $39K in Q4 2021.
  • 40 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2022.

Based on Spectrum Management Group's 13F filing for Q3 2022, filed 1 Nov 2022.